{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209833","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.395363+00:00","generated_at":"2026-06-11T15:05:13.845023+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Disc Medicine Q2 net loss $15.9M, cash $378M; BEACON bitopertin data positive","bullets":["Net loss $15.9M in Q2 2023 vs $9.6M in Q2 2022; R&D expense $12.1M, G&A $5.2M.","Cash and equivalents $377.6M as of June 30, 2023; expected to fund operations into 2026.","BEACON Phase 2 bitopertin data showed dose-dependent PPIX reduction, improved sunlight tolerance; well-tolerated.","Enrolling two Phase 1b/2 studies for DISC-0974 (NDD-CKD and myelofibrosis); initial data expected year-end 2023.","Completed upsized public offering in June 2023 for $157.8M gross proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209833","json":"https://secwatch.observer/filing/0001193125-23-209833.json","markdown":"https://secwatch.observer/filing/0001193125-23-209833.md","text":"https://secwatch.observer/filing/0001193125-23-209833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/0001193125-23-209833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/d471506d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:05:13.845023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bc01b3e6ffa55241b9fbbb21aeb08c967907cc9d","claim":"Disc Medicine, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $15.9 million for the quarter ended June 30, 2023.","evidence_excerpt":"Disc Medicine, Inc. (the \"Company\") announced its financial results for the quarter ended June 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523209833/0001193125-23-209833-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $15.9 million for the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}